Edgewise Gross Profit from 2010 to 2025

EWTX Stock

USD 28.00 0.42 1.48%

Edgewise Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Edgewise Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

-1.6 M

Current Value

-1.5 M

Quarterly Volatility

583.8 K

Credit Downgrade

Yuan Drop

Covid

Check Edgewise Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edgewise Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 17.1 M, Interest Income of 17.1 M or Depreciation And Amortization of 2.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.07. Edgewise financial statements analysis is a perfect complement when working with Edgewise Therapeutics Valuation or Volatility modules.

Check out the analysis of Edgewise Therapeutics Correlation against competitors.

For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Latest Edgewise Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Edgewise Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Edgewise Therapeutics minus its cost of goods sold. It is profit before Edgewise Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Edgewise Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edgewise Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Edgewise Gross Profit Regression Statistics

	Arithmetic Mean	(437,291)
	Geometric Mean	234,876
	Coefficient Of Variation	(133.50)
	Mean Deviation	445,062
	Median	(123,000)
	Standard Deviation	583,780
	Sample Variance	340.8B
	Range	1.6M
	R-Value	(0.74)
	Mean Square Error	164.4B
	R-Squared	0.55
	Significance	0
	Slope	(90,912)
	Total Sum of Squares	5.1T

Edgewise Gross Profit History

	2025	-1.5 M
	2024	-1.6 M
	2023	-1.7 M
	2022	-538 K
	2021	-272 K
	2020	-185 K

Other Fundumenentals of Edgewise Therapeutics

Gross Profit Margin

Edgewise Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Property Plant Equipment	Deferred Long Term Liab	Net Receivables	Capital Surpluse	Common Stock	Short Term Debt
Total Assets		0.98	0.95	-0.76	-0.91	0.98	-0.3	0.98	1.0	1.0	0.86	-0.98	-0.88	0.87	0.82	-0.67
Total Stockholder Equity	0.98		0.96	-0.81	-0.89	0.97	-0.48	1.0	0.98	0.98	0.85	-0.99	-0.88	0.87	0.81	-0.65
Net Tangible Assets	0.95	0.96		-0.73	-0.95	0.93	-0.49	0.96	0.95	0.95	0.93	-0.96	-0.9	0.88	0.85	-0.79
Net Debt	-0.76	-0.81	-0.73		0.52	-0.85	0.47	-0.81	-0.76	-0.77	-0.53	0.82	0.55	-0.49	-0.34	0.15
Retained Earnings	-0.91	-0.89	-0.95	0.52		-0.85	0.37	-0.89	-0.9	-0.9	-0.96	0.89	0.95	-0.93	-0.94	0.89
Accounts Payable	0.98	0.97	0.93	-0.85	-0.85		-0.34	0.97	0.98	0.98	0.85	-0.96	-0.87	0.85	0.75	-0.57
Total Liab	-0.3	-0.48	-0.49	0.47	0.37	-0.34		-0.48	-0.29	-0.29	-0.39	0.47	0.37	-0.37	-0.35	0.32
Net Invested Capital	0.98	1.0	0.96	-0.81	-0.89	0.97	-0.48		0.98	0.98	0.85	-0.99	-0.88	0.87	0.81	-0.65
Total Current Assets	1.0	0.98	0.95	-0.76	-0.9	0.98	-0.29	0.98		1.0	0.86	-0.98	-0.88	0.87	0.82	-0.67
Net Working Capital	1.0	0.98	0.95	-0.77	-0.9	0.98	-0.29	0.98	1.0		0.86	-0.98	-0.87	0.86	0.81	-0.66
Property Plant Equipment	0.86	0.85	0.93	-0.53	-0.96	0.85	-0.39	0.85	0.86	0.86		-0.83	-0.98	0.96	0.92	-0.86
Deferred Long Term Liab	-0.98	-0.99	-0.96	0.82	0.89	-0.96	0.47	-0.99	-0.98	-0.98	-0.83		0.84	-0.83	-0.78	0.65
Net Receivables	-0.88	-0.88	-0.9	0.55	0.95	-0.87	0.37	-0.88	-0.88	-0.87	-0.98	0.84		-0.98	-0.93	0.79
Capital Surpluse	0.87	0.87	0.88	-0.49	-0.93	0.85	-0.37	0.87	0.87	0.86	0.96	-0.83	-0.98		0.97	-0.82
Common Stock	0.82	0.81	0.85	-0.34	-0.94	0.75	-0.35	0.81	0.82	0.81	0.92	-0.78	-0.93	0.97		-0.92
Short Term Debt	-0.67	-0.65	-0.79	0.15	0.89	-0.57	0.32	-0.65	-0.67	-0.66	-0.86	0.65	0.79	-0.82	-0.92

Click cells to compare fundamentals

About Edgewise Therapeutics Financial Statements

Edgewise Therapeutics investors use historical fundamental indicators, such as Edgewise Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edgewise Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Gross Profit	-1.6 M	-1.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC